NPCE — NeuroPace Inc
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1528287 ·
Last close
$13.99
Market Cap
$480.20M
52W High
$18.23
52W Low
$12.66
ADV30
208,645
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 22,068,000 | 18,048,000 | -5,568,000 | -6,689,000 | 98,898,000 | 14,779,000 | 84,444,000 |
| Dec 2025 | 26,588,000 | 20,578,000 | -1,767,000 | -2,729,000 | 105,565,000 | 21,692,000 | 86,534,000 |
| Sep 2025 | 27,354,000 | 21,168,000 | -2,600,000 | -3,496,000 | 107,255,000 | 20,648,000 | 88,737,000 |
| Jun 2025 | 23,520,000 | 18,132,000 | -6,824,000 | -8,651,000 | 106,114,000 | 22,857,000 | 86,676,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,424,000
Investing CF
$-412,000
Financing CF
$-1,674,000
CapEx
$-412,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.65
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-559,104,000
Inventory
$16,694,000
Receivables
$14,788,000
ST Investments
$39,202,000
EBIT TTM
$-14,740,000
Pretax Income TTM
$-21,565,000
Interest Exp TTM
$6,825,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$106,993,000
EBITDA
$-11,877,000
Free Cash Flow
$-2,629,250
Enterprise Value
$498,428,608
Total Cash
$51,699,000
Total Debt
$69,931,000
Shares Out
34,324,274
Trailing EPS
$-0.47
Book Value
$0.35
ROE
-103.3%
ROA
-7.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 99,986,000 | -16,338,000 | -21,465,000 | 105,565,000 | 86,534,000 | — | -11,006,000 |
| Dec 2024 | 79,906,000 | -21,671,000 | -27,141,000 | 94,647,000 | 86,634,000 | — | -17,949,000 |
| Dec 2023 | 65,421,000 | -27,174,000 | -32,956,000 | 107,651,000 | 86,997,000 | — | -19,701,000 |
| Dec 2022 | 45,520,000 | -40,794,000 | -47,082,000 | 114,106,000 | 79,329,000 | — | -36,869,000 |
TTM Snapshot
Revenues TTM
$58,983,000
NetIncome TTM
$-32,577,000
OpCashFlow TTM
$0
Assets (Latest)
$94,647,000
Forward EPS
$-0.22
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $15.00 · spot: $13.99 · call volume: 38 · put volume: 6
Expected Move to 2026-09-18:
±$1.72
(12.29%) —
implied range
$12.27 –
$15.71
· ATM straddle on $15.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CLPT | ClearPoint Neuro, Inc. | $462.75M | $15.17 | — |
| SI | SHOULDER INNOVATIONS, INC. | $462.60M | $22.22 | — |
| SGHT | Sight Sciences, Inc. | $461.64M | $8.38 | — |
| TCMD | TACTILE SYSTEMS TECHNOLOGY INC | $529.16M | $23.36 | — |
| CARL | CARLSMED, INC. | $431.38M | $15.80 | — |
News headlines (Yahoo Finance, 1h cache)
NeuroPace Inc (NPCE) (Q2 2026) Earnings Call Highlights: Strong RNS Growth and AI Launch Offset ...
2026-08-19 01:01 · Yahoo
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates
2026-08-11 21:25 · Yahoo
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
2026-07-15 14:23 · Yahoo
NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant™
2026-06-27 15:31 · Yahoo
NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?
2026-06-11 15:30 · Yahoo
How The NeuroPace (NPCE) Investment Story Is Shifting Without A New Analyst Price Target
2026-06-02 22:07 · Yahoo
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?
2026-08-17 16:59 · Yahoo
NeuroPace FDA Bid for Expanded Epilepsy Use Stalls as Agency Seeks More Data
2026-07-28 22:04 · Yahoo
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
2026-08-17 17:17 · Yahoo
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?
2026-08-17 17:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.